170 related articles for article (PubMed ID: 37270418)
1. Comparison of the Centers for Disease Control (CDC) recommendations and the risk index for overdose or serious opioid-induced respiratory depression (RIOSORD) tool for guiding naloxone coprescribing.
Herndon CM; Kirby TR; Madison KJ; Kerr JL
J Opioid Manag; 2023; 19(2):111-116. PubMed ID: 37270418
[TBL] [Abstract][Full Text] [Related]
2. Development of a targeted naloxone coprescribing program in a primary care practice.
Wilson CG; Rodriguez F; Carrington AC; Fagan EB
J Am Pharm Assoc (2003); 2017; 57(2S):S130-S134. PubMed ID: 28189537
[TBL] [Abstract][Full Text] [Related]
3. Utilizing risk index for overdose or serious opioid-induced respiratory depression (RIOSORD) scores to prioritize offer of rescue naloxone in an outpatient veteran population: A telephone-based project.
Yates D; Frey T; Montgomery JC
Subst Abus; 2018; 39(2):182-184. PubMed ID: 29578839
[TBL] [Abstract][Full Text] [Related]
4. Validation of a Screening Risk Index for Serious Prescription Opioid-Induced Respiratory Depression or Overdose in a US Commercial Health Plan Claims Database.
Zedler BK; Saunders WB; Joyce AR; Vick CC; Murrelle EL
Pain Med; 2018 Jan; 19(1):68-78. PubMed ID: 28340046
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of an Opioid Overdose Composite Risk Score Cutoff in Active Duty Military Service Members.
Dunham JR; Highland KB; Costantino RC; Cliff Rutter W; Rittel AG; Kazanis WH; Palmrose GH
Pain Med; 2022 Oct; 23(11):1902-1907. PubMed ID: 35451483
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the Impact of a Clinical Decision Support Tool to Reduce Chronic Opioid Dose and Decrease Risk Classification in a Veteran Population.
Patel S; Carmichael JM; Taylor JM; Bounthavong M; Higgins DT
Ann Pharmacother; 2018 Apr; 52(4):325-331. PubMed ID: 29086587
[TBL] [Abstract][Full Text] [Related]
7. Rates of Physician Coprescribing of Opioids and Benzodiazepines After the Release of the Centers for Disease Control and Prevention Guidelines in 2016.
Jeffery MM; Hooten WM; Jena AB; Ross JS; Shah ND; Karaca-Mandic P
JAMA Netw Open; 2019 Aug; 2(8):e198325. PubMed ID: 31373650
[TBL] [Abstract][Full Text] [Related]
8. CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016.
Dowell D; Haegerich TM; Chou R
JAMA; 2016 Apr; 315(15):1624-45. PubMed ID: 26977696
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the Risk Index for Serious Prescription Opioid-Induced Respiratory Depression or Overdose in Patients with Cancer.
Okoroma NA; Nguyen P; Roeland EJ; Ma JD
J Pain Palliat Care Pharmacother; 2024 Jun; 38(2):131-137. PubMed ID: 38722684
[TBL] [Abstract][Full Text] [Related]
10. Naloxone coprescription in U.S. ambulatory care centers and emergency departments.
Gruver BR; Jiroutek MR; Kelly KE
J Am Pharm Assoc (2003); 2020; 60(5):e44-e49. PubMed ID: 32278514
[TBL] [Abstract][Full Text] [Related]
11. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
[TBL] [Abstract][Full Text] [Related]
12. Opioid Coprescribing with Sedatives after Implant-Based Breast Reconstruction.
Santosa KB; Wang CS; Hu HM; Mullen CR; Brummett CM; Englesbe MJ; Bicket MC; Myers PL; Waljee JF
Plast Reconstr Surg; 2022 Dec; 150(6):1224e-1235e. PubMed ID: 36103669
[TBL] [Abstract][Full Text] [Related]
13. Presence of opioid safety initiatives, prescribing patterns for opioid and naloxone, and perceived barriers to prescribing naloxone: Cross-sectional survey results based on practice type, scope, and location.
Kohan LR; Elmofty D; Pena I; Liao C
J Opioid Manag; 2021; 17(1):19-38. PubMed ID: 33735425
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Naloxone Coprescribing Mandates on Opioid-Involved Overdose Deaths.
Sohn M; Delcher C; Talbert JC; Cheng Y; Xu Y; Jadhav ED; Freeman PR
Am J Prev Med; 2023 Apr; 64(4):483-491. PubMed ID: 36496279
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a pharmacist-led naloxone coprescribing program in primary care.
Cariveau D; Fay AE; Baker D; Fagan EB; Wilson CG
J Am Pharm Assoc (2003); 2019; 59(6):867-871. PubMed ID: 31466899
[TBL] [Abstract][Full Text] [Related]
16. Assessment of a Naloxone Coprescribing Alert for Patients at Risk of Opioid Overdose: A Quality Improvement Project.
Nelson SD; McCoy AB; Rector H; Teare AJ; Barrett TW; Sigworth EA; Chen Q; Edwards DA; Marcovitz DE; Wright A
Anesth Analg; 2022 Jul; 135(1):26-34. PubMed ID: 35343932
[TBL] [Abstract][Full Text] [Related]
17. State Laws That Require Coprescribing Opioids and Naloxone and Codispensing Practices.
Tormohlen KN; Schmid I; Stuart EA; Davis C; McGinty EE
Am J Prev Med; 2024 Jan; 66(1):138-145. PubMed ID: 37739192
[TBL] [Abstract][Full Text] [Related]
18. Naloxone acceptance by outpatient veterans: A risk-prioritized telephone outreach event.
Wu S; Frey T; Wenthur CJ
Res Social Adm Pharm; 2021 May; 17(5):1017-1020. PubMed ID: 32980236
[TBL] [Abstract][Full Text] [Related]
19. Vital Signs: Pharmacy-Based Naloxone Dispensing - United States, 2012-2018.
Guy GP; Haegerich TM; Evans ME; Losby JL; Young R; Jones CM
MMWR Morb Mortal Wkly Rep; 2019 Aug; 68(31):679-686. PubMed ID: 31393863
[TBL] [Abstract][Full Text] [Related]
20. Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain.
Coffin PO; Behar E; Rowe C; Santos GM; Coffa D; Bald M; Vittinghoff E
Ann Intern Med; 2016 Aug; 165(4):245-52. PubMed ID: 27366987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
